US FDA declines to approve higher-dose of Biogen's genetic disorder drug
Refinitiv1分未満で読めます
The U.S. Food and Drug Administration has declined to approve a higher dose version of Biogen's 
BIIB drug for a rare genetic disorder that causes progressive muscle weakness, dealing a setback to the company's efforts to strengthen its position in a competitive market, the company said on Tuesday.
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう